SCOPUS 정보 검색 플랫폼

Neurology

Volumn 77, Issue 15, 2011, Pages 1414-1415

Is levodopa toxic?: Insights from a brain bank

(3) LeWitt, Peter A b,c Dubow, Jordan c Singer, Carlos a

a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE (United States)

b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE (United States)

c HENRY FORD HOSPITAL (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROGEN PEROXIDE; HYDROXYL GROUP; LEVODOPA; PLACEBO; REACTIVE OXYGEN METABOLITE; SEMIQUINONE; SUPEROXIDE;

CELL VIABILITY; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE COURSE; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG COST; DRUG USE; EDITORIAL; GLIA; HEALTH CARE FACILITY; HUMAN; LEWY BODY; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NEUROTOXICITY; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA PARS COMPACTA; UNSPECIFIED SIDE EFFECT;

EID: 82955168000 PISSN: 00283878 EISSN: 1526632X Source Type: Journal
DOI: 10.1212/WNL.0b013e31823435a4 Document Type: Editorial

Times cited : (8)

References (11)

1
- 57349093766
- Levodopa for the treatment of parkinson's disease
- LeWitt PA. Levodopa for the treatment of Parkinson's disease. N Engl J Med 2008;359:2468-2476.
- (2008) N Engl J Med , vol.359 , pp. 2468-2476
- LeWitt, P.A.¹

2
- 28444499344
- Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson's disease
- DOI 10.1007/s10928-005-0055-x
- Chan PL, Nutt JG, Holford NH. Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson's disease. J Pharmacokinet Pharmacodyn 2005;32:459-484. (Pubitemid 41738436)
- (2005) Journal of Pharmacokinetics and Pharmacodynamics , vol.32 , Issue.3-4 , pp. 459-484
- Chan, P.L.S.¹ Nutt, J.G.² Holford, N.H.G.³

3
- 0032730204
- Levodopa in the treatment of parkinson's disease: A consensus meeting
- Agid Y, Ahlskog E, Albanese A, et al. Levodopa in the treatment of Parkinson's disease: a consensus meeting. Mov Disord 1999;14:911-913.
- (1999) Mov Disord , vol.14 , pp. 911-913
- Agid, Y.¹ Ahlskog, E.² Albanese, A.³

4
- 4644314827
- Levodopa in the treatment of Parkinson's disease: Current controversies
- DOI 10.1002/mds.20243
- Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson's disease: the second consensus meeting. Mov Disord 2004;19:997-1005. (Pubitemid 39302831)
- (2004) Movement Disorders , vol.19 , Issue.9 , pp. 997-1005
- Olanow, C.W.¹ Agid, Y.² Mizuno, Y.³ Albanese, A.⁴ Bonucelli, U.⁵ Damier, P.⁶ De Yebenes, J.⁷ Gershanik, O.⁸ Guttman, M.⁹ Grandas, F.¹⁰ Hallett, M.¹¹ Hornykiewicz, O.¹² Jenner, P.¹³ Katzenschlager, R.¹⁴ Langston, W.J.¹⁵ LeWitt, P.¹⁶ Melamed, E.¹⁷ Mena, M.A.¹⁸ Michel, P.P.¹⁹ Mytilineou, C.²⁰ more..

5
- 82955167998
- Does levodopa accelerate the pathologic process in Parkinson disease brain?
- Parkkinen L, O'Sullivan SS, Kuoppamäki M, et al. Does levodopa accelerate the pathologic process in Parkinson disease brain? Neurology 2011;77;1420-1426.
- (2011) Neurology , vol.77 , pp. 1420-1426
- Parkkinen, L.¹ O'Sullivan, S.S.² Kuoppamäki, M.³

6
- 0030028316
- Evaluation of the pro-oxidant and antioxidant actions of L-DOPA and dopamine in vitro: Implications for Parkinson's disease
- Spencer JP, Jenner A, Butler J, et al. Evaluation of the pro-oxidant and antioxidant actions of L-DOPA and dopamine in vitro: implications for Parkinson's disease. Free Radic Res 1996;24:95-105. (Pubitemid 26035630)
- (1996) Free Radical Research , vol.24 , Issue.2 , pp. 95-105
- Spencer, J.P.E.¹ Jenner, A.² Butler, J.³ Aruoma, O.I.⁴ Dexter, D.T.⁵ Jenner, P.⁶ Halliwell, B.⁷

7
- 0037378026
- Oxidative stress in Parkinson's disease
- DOI 10.1002/ana.10483
- Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003;53(suppl 3):S26-S38. (Pubitemid 36368560)
- (2003) Annals of Neurology , vol.53 , Issue.SUPPL. 3
- Jenner, P.¹

8
- 0027937548
- Oxidative stress: Free radical production in neural degeneration
- DOI 10.1016/0163-7258(94)90055-8
- Götz ME, Künig G, Riederer P, Youdim MB. Oxidative stress: free radical production in neural degeneration. Pharmacol Ther 1994;63:37-122. (Pubitemid 24250150)
- (1994) Pharmacology and Therapeutics , vol.63 , Issue.1 , pp. 37-122
- Gotz, M.E.¹ Kunig, G.² Riederer, P.³ Youdim, M.B.H.⁴

9
- 0029002838
- Cultured rat striatal and cortical astrocytes protect mesencephalic dopaminergic neurons against hydrogen peroxide toxicity independent of their effect on neuronal development
- Langeveld CH, Jongenelen CA, Schepens E, et al. Cultured rat striatal and cortical astrocytes protect mesencephalic dopaminergic neurons against hydrogen peroxide toxicity independent of their effect on neuronal development. Neurosci Lett 1995;192:13-16.
- (1995) Neurosci Lett , vol.192 , pp. 13-16
- Langeveld, C.H.¹ Jongenelen, C.A.² Schepens, E.³

10
- 0031726193
- A synergistic neurotrophic response to l-dihydroxyphenylalanine and nerve growth factor
- Mena MA, Davila V, Bogaluvsky J, Sulzer D. A synergistic neurotrophic response to L-dihydroxyphenylalanine and nerve growth factor. Mol Pharmacol 1998;54:678-686. (Pubitemid 28480971)
- (1998) Molecular Pharmacology , vol.54 , Issue.4 , pp. 678-686
- Mena, M.A.¹ Davila, V.² Bogaluvsky, J.³ Sulzer, D.⁴

11
- 19744378296
- Levodopa and the progression of parkinson's disease
- Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351:2498-2508.
- (2004) N Engl J Med , vol.351 , pp. 2498-2508
- Fahn, S.¹ Oakes, D.² Shoulson, I.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.